Výsledky vyhledávání - "Anne Parneix-Spake"

Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial

Autor: Adelaide A Hebert, Thomas Hultsch, P. R. Gallagher, C. McCormick, Anne Parneix-Spake, Jonathan M. Spergel, Mark Boguniewicz, Amy S. Paller

Publikováno v: British Journal of Dermatology. 157:378-381

Summary Background Combination therapy with pimecrolimus cream 1%, a topical calcineurin inhibitor (TCI), and fluticasone propionate cream 0·05% (FP), a mid-potency topical corticosteroid, may have a synergistic effect for treatment of atopic dermat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbad728b54ef5756f6d70bfb0c23c1cb
https://doi.org/10.1111/j.1365-2133.2007.08001.x

Zobrazit plný text záznamu

Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis

Autor: Erin M. Warshaw, Sarah A. Zeller, Julie C. Schultz, Calogera L. McCormick, Ross Jon Wohlhuter, An Liu, H. Irving Katz, Sacharitha Bowers, Anne Parneix-Spake, Rachel A. Wenner

Publikováno v: Journal of the American Academy of Dermatology. 57:257-264

Background Seborrheic dermatitis is commonly treated with anti-inflammatory products, including topical corticosteroids. Pimecrolimus cream 1% also exerts anti-inflammatory activity by inhibiting T-cell cytokine production. Objective We sought to com

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8cea1f00ea51037e8d37b6e279223af
https://doi.org/10.1016/j.jaad.2006.11.007

Zobrazit plný text záznamu

An Exploratory study to evaluate the efficacy of pimecrolimus cream 1% for the treatment of pityriasis alba

Autor: Wayne H Fujita, Anne Parneix-Spake, Calogera L. McCormick

Publikováno v: International Journal of Dermatology. 46:700-705

Background Use of topical corticosteroids for the treatment of pityriasis alba is limited by their potential side-effects, such as skin atrophy especially with long-term use on the face. Pimecrolimus cream 1% is a topical calcineurin inhibitor that h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f577ffa76c36505e05a611dabffd8022
https://doi.org/10.1111/j.1365-4632.2007.03145.x

Zobrazit plný text záznamu

Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double-blind, randomized study

Autor: Alan Menter, Alice B. Gottlieb, Zoe Diana Draelos, Mark Ling, Carin H. Gribetz, Thomas Hultsch, Nardo Zaias, Mark Lebwohl, Anne Parneix-Spake, Diana M. Chen, David M. Pariser

Publikováno v: Journal of the American Academy of Dermatology. 51:731-738

Background Inverse psoriasis can be difficult to treat because of the high sensitivity of intertriginous areas to cutaneous side effects, such as irritation and striae. Pimecrolimus, a well-tolerated, nonatrophogenic, skin-selective inflammatory cyto

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4fb47e7fa466a5b12c539365f5b092eb
https://doi.org/10.1016/j.jaad.2004.06.010

Zobrazit plný text záznamu

Primary cutaneous pleomorphic small T-cell lymphoma. A review of 11 cases. The French Study Group on Cutaneous Lymphomas

Autor: Janine Wechsler, Jean-Pierre Farcet, Martine Bagot, Marie-Helene Delfau, Friedmann D, Anne Parneix-Spake, J. Revuz, Eric Estève, Loïc Vaillant, de Muret A

Publikováno v: Archives of Dermatology. 131:1009-1015

Background and design Cutaneous pleomorphic small T-cell lymphoma is a rare, recently recognized lymphoma, different from mycosis fungoides and Sezary syndrome. Only a few cases have been reported and no treatment modalities have been defined. We rev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::75494d89bb748cd9f16039a03528ac3a
https://doi.org/10.1001/archderm.131.9.1009

Zobrazit plný text záznamu

Retrospective analysis of pimecrolimus cream 1% for treatment of facial vitiligo

Autor: Flor A, Mayoral, Janelle M, Vega, Henry, Stavisky, Calogera L, McCormick, Anne, Parneix-Spake

Publikováno v: Journal of drugs in dermatology : JDD. 6(5)

To explore the effectiveness of pimecrolimus cream 1% used twice daily (BID) for the treatment of facial vitiligo.Patients who had used pimecrolimus cream 1% monotherapy BID for at least 3 months and who had photographs taken at baseline and after in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c881d8e289fd76d429f50206892429f8
https://pubmed.ncbi.nlm.nih.gov/17679186

Zobrazit plný text záznamu

Pimecrolimus cream 1% for treatment of vulvar lichen simplex chronicus: an open-label, preliminary trial

Autor: Lara J. Burrows, Calogera L. McCormick, Andrew T. Goldstein, Anne Parneix-Spake

Publikováno v: Gynecologic and obstetric investigation. 64(4)

Background: To evaluate efficacy and safety of pimecrolimus cream 1% twice daily for treatment of vulvar lichen simplex chronicus (LSC). Methods: Patients in this 12-week, open-label study had biopsy-proven vulvar LSC. Inclusion criteria were patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::695d1919f305a1740bf888f3a2feab92
https://pubmed.ncbi.nlm.nih.gov/17664878

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání